News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase III
Puma Biotechnology (PBYI) Shares Soar On Breast Cancer Drug Results 7/23/2014
Pfizer Inc. (PFE) Backs Out of Funding Puma Biotechnology (PBYI) Cancer Drug Trials 7/23/2014
CEL-SCI (CVM) Has Been Cleared to Begin Patient Enrollment 7/23/2014
Major Advance In UCB Pipeline: Positive Topline Phase 3 Results For brivaracetam In Epilepsy Patients With Partial-Onset Seizures 7/23/2014
ViiV Healthcare: HIV Combo Therapy Candidate Fails Phase 3 7/22/2014
PSI CRO Launches A Global Phase 3 Rare Disease Trial 7/22/2014
Enrollment Commences In NeuroSigma, Inc.-Sponsored Pediatric Clinical Trial For The Treatment Of Lennox-Gastaut Syndrome 7/22/2014
Antares Pharma, Inc. (ATRS) Announces First Patient Dosed in Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males 7/22/2014
Argos Therapeutics, Inc. (ARGS) Presents Data Showing The Impact Of HIV Antigen Sequence Divergence On Durable Viral Control Following Treatment With Autologous Immune Therapy 7/22/2014
Nymox Pharmaceutical (NYMX) Announces Positive Efficacy Results In Phase 3 Repeat Injection Trial Of NX-1207 For BPH 7/22/2014
Synta Pharmaceuticals (SNTA) Announces Advancement Of Ganetespib Into Phase 3 Extension Of AML LI-1 Study For Patients With AML And High-Risk MDS 7/22/2014
Amgen (AMGN) Thyroid Drug AMG 416 Succeeds In Late Stage Kidney Patient Trial 7/21/2014
Dipexium Pharmaceuticals (DPRX) Initiates Second Of Two Pivotal Phase 3 Clinical Trials Of Locilex® In Patients With Mild Infections Of Diabetic Foot Ulcers 7/21/2014
Braeburn Pharmaceuticals Enrolls First Patients In Late-Stage Clinical Study Of Probuphine® For Opioid Dependence 7/21/2014
Proteon Therapeutics, Inc. Initiates Phase 3 Clinical Study Of PRT-201 In Patients With Chronic Kidney Disease Undergoing Surgical Placement Of An Arteriovenous Fistula For Hemodialysis 7/21/2014
Regeneron Pharmaceuticals, Inc. (REGN) Release: Two-Year Results From Phase 3 VIVID-DME Trial Of EYLEA® (aflibercept) Injection For The Treatment Of Diabetic Macular Edema Show Sustained Improvement In Vision 7/18/2014
Genmab A/S (GEN.CO) Announces Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 7/18/2014
InterMune, Inc. (ITMN) Grabs FDA Breakthough Therapy Designation For IPF Drug Pirfenidone 7/18/2014
Agile Therapeutics, Inc. Announces Allowance Of Additional Patent Claims For Skinfusion® 7/18/2014
TauRx Therapeutics Achieves Enrollment Target In The First Of Its Two Phase III Clinical Trials Of LMTX™ In Alzheimer's Disease 7/17/2014
New England Journal Of Medicine Publishes Ipsen (IPN.PA)’s Somatuline® CLARINET® Phase III Results In Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors 7/17/2014
Dipexium Pharmaceuticals (DPRX) Initiates Pivotal Phase 3 Clinical Trial Of Locilex® In Patients With Mild Infections Of Diabetic Foot Ulcers 7/17/2014
CEL-SCI (CVM) Expands Its Phase 3 Head And Neck Cancer Trial Into Sri Lanka 7/17/2014
Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial For SD-809 In Tardive Dyskinesia 7/17/2014
Pfizer Inc. (PFE) Hemophilia B Treatment Regimen Meets Endpoint In Phase 3 Trial 7/16/2014
Boehringer Ingelheim Corporation's Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation 7/16/2014
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Begin Pivotal Phase 3 Trial For Triple Combination Treatment 7/16/2014
AVANIR Pharmaceuticals (AVNR) Announces Presentation Of Positive Early Results From Prism II Study 7/16/2014
Coherus Biosciences Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy) 7/16/2014
Rigel Pharmaceuticals, Inc. (RIGL) Initiates Phase 3 Studies Of Fostamatinib In ITP 7/16/2014
Exelixis, Inc. (EXEL) And Genentech (RHHBY)'s Melanoma Combination Drug Meets Main Goal In Phase 3 Study 7/15/2014
Neos Therapeutics Announces Positive Phase 3 Study Results For Its Methylphenidate Extended-Release (XR) Oral Disintegrating Tablet (ODT) In ADHD Patients 7/15/2014
Aerie Pharmaceuticals, Inc. (AERI) Initiates Phase 3 Registration Trials of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma 7/15/2014
Nymox Pharmaceutical (NYMX) Announces Completion Of Enrollment For Second BPH Re-Injection Study 7/15/2014
Eli Lilly and Company (LLY) Release: New Data Shows Cognitive Impairment Precedes And Predicts Subsequent Functional Impairment In Patients With Mild Alzheimer's Disease 7/15/2014
ZS Pharma (ZSPH) Completes Patient Enrollment In ZS004, Its Second Phase 3 Study Of ZS-9 In Patients With Hyperkalemia 7/15/2014
FDA Green Lights Starpharma Holdings Ltd's VivaGel Trial Design 7/14/2014
Synergy Pharmaceuticals Reaches Halfway Mark For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation 7/14/2014
Alcobra (ADHD) Completes Patient Recruitment In Phase 3 Clinical Trial Of MDX In Adult ADHD 7/14/2014
Basilea Pharmaceutica (BSLN.SW) Reports That Isavuconazole Receives Orphan Drug Designations In Europe For The Treatment Of Invasive Mold Infections 7/14/2014
FDA Places Regado Biosciences, Inc. (RGDO)'s Phase 3 Revolixys Trial On Clinical Hold 7/11/2014
Novartis AG (NVS)'s New Drug Secukinumab Shows Promise In Two Pivotal Phase 3 Trials 7/11/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Celgene (CELG)'s OTEZLA® Misses Mark In Phase 3 Spinal Arthritis Study 7/10/2014
SillaJen Lead Product Pexa-Vec Featured In "Nature Reviews Cancer" Article Summarizing The Potential Of Oncolytic Immunotherapy 7/10/2014
TransTech Pharma, Inc. Announces Agreement With FDA On Special Protocol Assessment For TTP488 Phase 3 Trial In Patients With Mild Alzheimer’s Disease 7/10/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
Vital Therapies, Inc. (VTI) (VTL) Reports On Clinical Trial Progress And EU Regulatory Advice 7/9/2014
La Jolla Pharmaceutical Company (LJPC) Announces Planned Initiation Of Phase 3 Registration Program For LJPC-501 In Resistant Hypotension 7/9/2014
Oxygen Biotherapeutics, Inc. (OXBT) Release: Recent Scientific Publications Highlight Potential Benefits Of Levosimendan In Cardiac Surgery And Additional Critical Care Conditions 7/9/2014
San Diego's Otonomy, Inc. Touts Positive Data From Two Phase 3 Trials Of Auripro™ 7/8/2014
Eli Lilly and Company (LLY) To Showcase Data From Its Alzheimer's Disease Portfolio At The Alzheimer's Association International Conference 2014 (AAIC 2014) 7/8/2014
CEL-SCI (CVM) Receives Regulatory Clearance To Expand CEL-SCI’S Phase 3 Head And Neck Cancer Trial Into Austria 7/8/2014
Regado Biosciences, Inc. (RGDO) Shares Nearly Halved After Announcing Trial Review; Stock Down -58.43% At Market Close (July 3, 2014) 7/7/2014
Endo International plc (ENDP), BioDelivery Sciences International (BDSI) Painkiller BEMA® Buprenorphine Effective In Phase 3 Study 7/7/2014
RegeneRx Biopharmaceuticals, Inc. (RGRX)’s Strategic Partner G-Treebnt Preparing For Phase 3 Dry Eye Trials In Asia With RGN-259 7/7/2014
Salix Pharmaceuticals, Ltd. (SLXP) Surges On Encouraging Phase 3 Results For Rifaximin; Stock Up +13.51% At Market Close (July 1, 2014) 7/2/2014
GlaxoSmithKline (GSK), Genmab A/S (GEN.CO) Leukemia Drug Ofatumumab Fails To Meet Main Trial Goal 7/2/2014
Synageva BioPharma (GEVA) Details Positive Phase 3 Data Of Sebelipase Alfa 7/1/2014
CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients with Myelofibrosis 7/1/2014
GlycoMimetics, Inc. (GLYC) Announces Agreement With FDA On Special Protocol Assessment For Phase 3 Clinical Trial Of Rivipansel (GMI-1070) 7/1/2014
Specialty Vaccine Company PaxVax, Inc. Announces Positive Efficacy Results For Phase 3 Cholera Challenge Study 7/1/2014
CEL-SCI (CVM) Reports 93 Percent Increase In Sequential Quarterly Patient Enrollment In Its Phase 3 Head And Neck Cancer Trial 7/1/2014
Merck & Co., Inc. (MRK)'s Pediatric Anti-Vomiting Drug Effective In Phase 3 Trial 6/30/2014
Taiho Oncology's Colorectal Cancer Drug TAS-102 Improves Overrall Survival In Phase 3 Trial 6/30/2014
Icon Bioscience Announces Early Completion Of Patient Enrollment In Its Phase 3 Study Of IBI-10090; Drug Addresses Market Need For Long-Acting Treatment Of Inflammation Post Cataract Surgery 6/30/2014
Alimera Sciences (ALIM)' ILUVIEN® Receives Positive Outcome Of Repeat-Use Procedure For 10 Additional European Countries 6/30/2014
PTC Therapeutics, Inc. (PTCT) Initiates Confirmatory Phase 3 Clinical Trial Of Translarna™ (Ataluren) In Patients With Nonsense Mutation Cystic Fibrosis (nmCF) 6/30/2014
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014
Amicus Therapeutics, Inc. (FOLD) Provides Updates And Final Analysis Plan For Phase 3 Fabry Monotherapy Study 012 6/30/2014
CRO Health Decisions, Evofem Lock Database In Largest Contraceptive Trial Of Its Type 6/27/2014
H. Lundbeck A/S (LUN.CO)'s Late Stage Trials For Stroke Failed To Meet Primary Endpoint 6/27/2014
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/27/2014
Bristol-Myers Squibb Company (BMY) Stops Skin Study On Positive Phase 3 Data 6/26/2014
Boehringer Ingelheim Corporation's Investigational Antidote For Pradaxa® Grabs FDA Breakthrough Therapy Designation 6/26/2014
Merrimack Pharmaceuticals Inc. (MACK) Presents Data From Phase 3 NAPOLI-1 Study At The ESMO 16th World Congress On Gastrointestinal Cancer 6/26/2014
AbbVie (ABBV) Announces Initiation Of Pivotal Phase 3 Study Of Veliparib (ABT-888) In Patients With Advanced Breast Cancer 6/26/2014
ZS Pharma (ZSPH) Announces Start Of Enrollment Of Phase 3 Long-Term Maintenance Study Of ZS-9 In Patients With Hyperkalemia 6/26/2014
BioDelivery Sciences International (BDSI) Announces Completion Of Patient Enrollment In Its Initial Phase 3 Trial Of Clonidine Topical Gel For Painful Diabetic Neuropathy 6/26/2014
Due To Positive Feedback, Ampio Pharmaceuticals, Inc. (AMPE) Closes Enrollment Of OptimEyes Study, Will Present Data To FDA For Guidance 6/25/2014
FDA Requests More Data For Basilea Pharmaceutica (BSLN.SW)'s Pneumonia Drug Ceftobiprole; Stock Drops -8.15% At Market Close (June 25, 2014) 6/25/2014
Vertex Pharmaceuticals (MA) (VRTX) Rockets As Cystic Fibrosis Combo Succeeds In Two Late Stage Trials 6/25/2014
Ligand Pharmaceuticals Inc. (LGND) Partner GlaxoSmithKline (GSK) Announces The Start Of A Phase 3 Study With Eltrombopag In Patients With Myelodysplastic Syndromes 6/25/2014
Orexo AB (ORXOF) Release: Top-Line Data From A Phase 3 Clinical Trial Demonstrates That Zubsolv® Is As Effective As Suboxone® Film In The Treatment Of Opioid Dependence 6/25/2014
AVANIR Pharmaceuticals (AVNR) Announces Three Data Presentations Related To AVP-825 For The Acute Treatment Of Migraine At The American Headache Society Annual Meeting 6/24/2014
Taxus Cardium (CRXM) Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy Of Generx® Angiogenic Gene Therapy For Myocardial Ischemia Due To Coronary Artery Disease At The 2014 Biotechnology Industry Organization (BIO) International Convention 6/24/2014
Cardium Therapeutics, Inc. (CXM) Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy Of Generx® Angiogenic Gene Therapy For Myocardial Ischemia Due To Coronary Artery Disease At The 2014 Biotechnology Industry Organization (BIO) International Convention 6/24/2014
Cystic Fibrosis Foundation Applauds Successful Phase 3 Results Of Ivacaftor (Kalydeco™) And Lumacaftor (VX-809) Drug Combination For People With Two Copies Of F508del Mutation Of Cystic Fibrosis 6/24/2014
Auspex Pharmaceuticals Announces Data From Interim Analysis Of ARC-HD Switch Trial Demonstrating Clinical Activity Of SD-809 6/24/2014
CorMedix (CRMD) Finalizes Pivotal Phase 3 Study Protocol For FDA 6/24/2014
Burzynski Research Institute Announces Lifting Of The FDA Partial Clinical Hold - Phase 3 Clinical Study Agreed Upon 6/24/2014
Positive New Phase 3a Data On Novo Nordisk A/S (NVO)'s Liraglutide 6/23/2014
Aradigm Corporation (ARDM) Announces The Dosing Of The First Patient In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) 6/23/2014
Coherus Biosciences Announces Initiation Of Phase 3 Trial Of Chs-0214 (Investigational Etanercept Biosimilar) In Rheumatoid Arthritis 6/23/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Positive Two-Year Results From Pivotal Phase 3 Study Of Envarsus® XR (Tacrolimus Extended-Release Tablets) In De Novo Kidney Transplant Patients 6/23/2014
Clarus Therapeutics Presents Phase 3 Data For REXTORO® For Men With Hypogonadism 6/23/2014
Orexo AB (ORXOF) Release: Positive Top-Line Results From Two Phase 3 Clinical Trials That Assessed Zubsolv® For Induction Of Buprenorphine Maintenance Therapy 6/23/2014
Regado Biosciences, Inc. (RGDO)' REG2 Demonstrates Dose And Concentration-Dependent Suppression Of Thrombin Generation 6/23/2014
The European Medicines Agency And FDA Grant Orphan Drug Designation To PHARNEXT's PXT-3003 For The Treatment Of Charcot-Marie-Tooth Disease Type 1A 6/23/2014
NephroGenex (NRX) Initiates Pivotal Phase 3 Study With Novel Treatment To Slow Progression Of Diabetic Kidney Disease 6/20/2014
TetraPhase Pharmaceuticals Completes Enrollment in Lead-in Portion of IGNITE 2 Eravacycline Phase 3 Clinical Trial in cUTI 6/19/2014
Successful Phase 3 Results For Alkermes plc (ALKS)'s Schizophrenia Drug Aripiprazole Lauroxil 6/19/2014
AstraZeneca PLC (AZN) Release: Data Published In The New England Journal of Medicine Demonstrate Naloxegol Improved Opioid-Induced Constipation In Chronic Pain Patients 6/19/2014
Provectus Biopharmaceuticals Inc. To Hold Conference Call Today To Detail Outline Of Phase 3 Clinical Trial Of PV-10 In Melanoma Treatment 6/19/2014
Two-Year Results From Pfizer Inc. (PFE)’s XELJANZ® (Tofacitinib Citrate) ORAL Start Study Published In The New England Journal of Medicine 6/19/2014
Kala Pharmaceuticals Initiates Phase 3 Clinical Trial for Treatment of Post Surgical Ocular Inflammation and Phase 2 Clinical Trial in Dry Eye 6/19/2014
Boehringer Ingelheim (Canada) Ltd. Release: Study Findings Show Tiotropium Respimat®* Well-Tolerated And Effective In Japanese Patients With Symptomatic Asthma 6/19/2014
Actelion Ltd. (ALIOF.PK) Soars As Heart-Lung Drug Selexipag Meets Main Goal In Late-Stage Study 6/18/2014
Biogen Idec, Inc. (Massachusetts) (BIIB), AbbVie (ABBV)'s Once-A-Month Drug Daclizumab Slows Multiple Sclerosis Episodes, Safety Issues Reoccur 6/17/2014
Intarcia Therapeutics, Inc.'s Once-A-Year Diabetes Drug ITCA 650 Impresses In Phase 3 Trial 6/17/2014
AmVac AG Initiates Phase III Trial With Its Lead Vaccine Gynevac For The Treatment Of Bacterial Vaginosis 6/17/2014
Upsher-Smith Laboratories Release: Qudexy™ XR (Topiramate) Extended-Release Capsules Phase 3 Data Published In Epilepsia 6/17/2014
Janssen Research & Development Release: New Long-Term Data Show INVOKANA® (canagliflozin) Lowers Blood Glucose In Older Patients With Type 2 Diabetes Inadequately Controlled On Other Therapies 6/17/2014
Nymox Pharmaceutical (NYMX) Reports Positive Update On Nerve Sparing And Sexual Function Preservation In Men Treated With NX-1207 6/17/2014
Merrimack Pharmaceuticals Inc. (MACK) Announces Oral Presentation Of Additional Data Results In Phase 3 NAPOLI-1 Study At The ESMO 16th World Congress On Gastrointestinal Cancer 6/17/2014
Eli Lilly and Company (LLY)'s Once-Weekly Dulaglutide Shows Similar Reductions In Average Blood Glucose Levels As Once-Daily Liraglutide In Head-to-Head Trial 6/17/2014
Eli Lilly and Company (LLY) Announces Detailed Results From Two Phase III Studies Testing Both Doses Of Dulaglutide Vs. Insulin Glargine 6/17/2014
Eisai Inc. (ESALF.PK)'s Antiepileptic Drug Perampanel Meets Primary Endpoint In Phase 3 Study 6/16/2014
Sanofi (France) (SAN.PA) Toujeo Shows Great Promise As Lantus Successor 6/16/2014
Novo Nordisk A/S (NVO)'s Big-Selling Diabetes Drug Victoza Appears Effective For Weight Loss 6/16/2014
AbbVie (ABBV)'s Chronic Hepatitis C Regimen Gets Priority Review From The FDA 6/16/2014
Novo Nordisk A/S (NVO) Release: Phase 3a Data Showed Liraglutide 3 Mg Demonstrated Significantly Greater Weight Loss Compared To Placebo In Adults With Obesity And Type 2 Diabetes 6/16/2014
Studies Show Investigational New Insulin Glargine Product From Eli Lilly and Company (LLY) And Boehringer Ingelheim Corporation Similar Safety And Efficacy Profile To Lantus® 6/16/2014
Eli Lilly and Company (LLY) Release: Type 2 Diabetes: Investigational Compound empagliflozin As An Add-On Therapy Significantly Reduced Blood Glucose And Body Weight In Two Newly Presented Phase 3 Trials 6/16/2014
Celgene International Sárl (CELG) Release: Results From Phase III Study (AML-001) Of VIDAZA® (Azacitidine For Injection) In Acute Myeloid Leukemia Presented At European Hematology Association 6/16/2014
Celgene International Sárl (CELG) Release: Retrospective Analysis Of Overall Survival Adjusting For Patient Crossover In Phase III Study Of POMALYST®/IMNOVID® (Pomalidomide) In Previously Treated Multiple Myeloma Presented At EHA 6/16/2014
Gilead Sciences, Inc. (GILD) Announces Phase 3 Data Showing That The Fixed-Dose Combination Of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients With Chronic Hepatitis C In Japan 6/16/2014
Eli Lilly and Company (LLY) Release: Type 2 Diabetes: Jardiance® (Empagliflozin) As An Add-On Therapy Significantly Reduced Blood Glucose And Body Weight In Two Newly Presented Phase 3 Trials 6/16/2014
Eli Lilly and Company (LLY)'s Once-Weekly Dulaglutide Shows Similar Reductions In Average Blood Glucose Levels As Once-Daily Liraglutide In Head-to-Head Trial 6/16/2014
Novo Nordisk A/S (NVO) Combination Diabetes Drug IDegLira Effective After 1 Year Study 6/16/2014
Mast Therapeutics (MSTX) Initiates Sub-Study Within Phase 3 EPIC Trial 6/16/2014
Intarcia Therapeutics, Inc. Presents Interim Phase 3 Data At American Diabetes Association Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar In Patients With Very Poorly Controlled Diabetes 6/16/2014
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Tout Positive Phase 3 Data For Rheumatoid Drug Sarilumab 6/13/2014
Ligand Pharmaceuticals Inc. (LGND) Partner GlaxoSmithKline (GSK)'s Phase 3 PETIT2 Study Meets Primary Endpoint 6/13/2014
US FDA Advisory Committee Recommends No Cardiovascular Outcomes Trial For Peripherally-Acting Mu-Opioid Receptor Antagonist (Pamora) Class Including Movantik 6/13/2014
All Eyes Are On AstraZeneca PLC (AZN) As Its Diabetes Drugs Go Under The Spotlight At Major Scientific Meeting 6/12/2014
Medimetriks Pharmaceuticals, Inc. Announces That The Second Phase 3 Study For Ozenoxacin Has Been Initiated By Ferrer 6/12/2014
Eli Lilly and Company (LLY)'s Cyramza Misses Primary Endpoint In Critical Phase 3 Study 6/12/2014
GlaxoSmithKline (GSK) And Theravance, Inc. (THRX) Announce Positive Data From Two Studies Evaluating The Efficacy And Safety Of Incruse® Ellipta® When Added To Relvar®/Breo® Ellipta(®) In Patients With COPD 6/12/2014
Phase 3 Data Demonstrate Comparability Of Epirus’ BOW015 To Remicade® For Treatment Of Rheumatoid Arthritis 6/12/2014
Iroko Pharmaceuticals Release: SoluMatrix® Meloxicam Demonstrates Significant Efficacy At 30 Percent Lower Doses In The Treatment Of Osteoarthritis 6/12/2014
Vertex Pharmaceuticals (MA) (VRTX) Announces Presentation Of New KALYDECO™ (Ivacaftor) Data At European Cystic Fibrosis Society Conference 6/12/2014
Cardium Therapeutics, Inc. (CXM) To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 Biotechnology Industry Organization (BIO) International Convention 6/12/2014
Nymox Pharmaceutical (NYMX) Reports Positive New Safety Study Data For Phase 3 BPH Drug 6/12/2014
Iroko Pharmaceuticals Takes Low Dose Approach To Osteoarthritis Pain Meds To Avoid Adverse Events In Phase 3 Study 6/12/2014
Ambit Biosciences Announces Presentation Of Data From Clinical Investigations Of Quizartinib At The 19th Congress Of The European Hematology Association 6/12/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Put Out Positive Update On Two Phase 3 Ellipta COPD Studies 6/11/2014
EULAR: Romosozumab Significantly Increases Bone Mineral Density And Bone Content Compared With Teriparatide 6/11/2014
Otsuka Pharmaceutical Development & Commercialization, Inc. Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease 6/11/2014
Bristol-Myers Squibb Company (BMY) Release: AVERT Trial Demonstrates High Rates Of DAS-Defined Remission With Orencia® (Abatacept) In Combination With Methotrexate (MTX) In Adult Patients With Early Rheumatoid Arthritis (RA) 6/11/2014
Celgene (CELG) Release: Oral OTEZLA® (Apremilast) Monotherapy Showed Long-Term Clinical Benefits In DMARD-Naïve Patients With Active Psoriatic Arthritis 6/11/2014
Navidea Biopharmaceuticals (NAVB)’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection Demonstrates Preferential Accumulation In Tumor-Positive Sentinel Lymph Nodes In Post-Hoc Analysis 6/11/2014
Celgene (CELG) Release: Oral OTEZLA® (Apremilast) Showed Long-Term Clinical Benefits In Patients With Active Psoriatic Arthritis 6/11/2014
Celator Pharmaceuticals, Inc. Announces Data And Safety Monitoring Board Recommendation To Continue Phase 3 Study Of CPX-351 6/11/2014
Navidea Biopharmaceuticals (NAVB) Announces Positive Lymphoseek® (Technetium Tc 99m Tilmanocept) Injection Results On Injection Timing And Surgery Across Multiple Solid Tumor Types 6/11/2014
Makindus Receives Orphan Designation For MI-100 For Stargardt's Disease 6/10/2014
AVANIR Pharmaceuticals (AVNR)' Migraine Drug AVP-825 Meets Primary Endpoint in Phase 3 Trial 6/10/2014
Janssen Research & Development To Present Latest Data For Type 2 Diabetes Treatment INVOKANA® (canagliflozin) At American Diabetes Association 74th Scientific Sessions® 6/10/2014
Northwest Biotherapeutics (NWBO) Release: DCVAX®-L Phase 3 Trial Initiated In Germany 6/10/2014
Alkermes plc (ALKS) Announces Initiation Of FORWARD-3 And FORWARD-4 Efficacy Studies In Pivotal Program For ALKS 5461 For Treatment Of Major Depressive Disorder 6/10/2014
Adamas Pharmaceuticals (ADMS) Initiates Phase 3 Trial For ADS-5102 In Parkinson's Disease Patients With Levodopa-Induced Dyskinesia 6/10/2014
GlaxoSmithKline (GSK) Launches Huge Phase 3 Study For Heart Drug Losmapimod 6/9/2014
ALK-Abello A/S Presents Phase 3 Data On House Dust Mite SLIT-Tablet At EAACI Annual Congress In Copenhagen 6/9/2014
Elite Pharmaceuticals, Inc. (ELI) Begins Human Abuse Liability Studies For ELI-200 6/9/2014
Immunomedics, Inc. (IMMU) Release: Scientific Data On Epratuzumab In Systemic Lupus Erythematosus To Be Presented At EULAR 2014 6/9/2014
Merck & Co., Inc. (MRK) Release: First Patient Enrolled In New Phase 3 Trial Program Investigating A Once-Daily Dosing Regimen Of ISENTRESS® (Raltegravir) 6/6/2014
GW Pharmaceuticals Announces Epidiolex® Receives Fast Track Designation From FDA For The Treatment Of Dravet Syndrome 6/6/2014
Alchemia Updates Timeline For Completion Of Pivotal Phase III Trial Of HA-Irinotecan In Metastatic Colorectal Cancer 6/6/2014
Cubist Pharmaceuticals, Inc. (CBST) Announces Publication Of Pivotal Data From SIVEXTRO™ (tedizolid phosphate) ESTABLISH-2 Clinical Trial In The Lancet Infectious Diseases 6/6/2014
The New England Journal of Medicine Publishes Data From Durata Therapeutics, Inc.  (DRTX)'s Discover Program 6/5/2014
RedHill Biopharma Ltd. (RDHL) Announces New RHB-104 Patent In Japan And Provides Update On Phase 3 Crohn's Program 6/5/2014
The Medicines Company (MDCO) Release: ORBACTIV™ (Oritavancin) Phase 3 Trial Results Published In The New England Journal of Medicine 6/5/2014
Promedior Announces Presentation Of Interim Phase 2 Data On PRM-151 In Myelofibrosis At The Upcoming Congress Of European Hematology Association 6/5/2014
Vertex Pharmaceuticals (MA) (VRTX) Reports Positive Ivacaftor Study Data, Plans To Initiate Larger Phase 3 Study 6/4/2014
Jiangsu Hengrui Medicine Co. Ltd. Reports Positive Phase 3 Data For Cancer Drug 6/4/2014
Autifony Therapeutics Awarded £2.2 Million To Progress First-In-Class Drug For Tinnitus Into Phase 2a Study 6/4/2014
Celator Pharmaceuticals, Inc. Reaches 75 Percent Enrollment Milestone In Phase 3 Study Of CPX-351 6/4/2014
Janssen Pharmaceutical Inc. 's Ibrutinib Triples Progression-Free Survival, Doubles Overall Survival In Phase 3 Leukemia Study 6/3/2014
Eli Lilly and Company (LLY)'s CYRAMZA™ (ramucirumab) Significantly Improves Overall Survival In Phase 3 Non-Small Cell Lung Cancer Study 6/3/2014
Novartis AG (NVS)'s Bone Marrow Drug LBH589 Improves Progression-Free Survival In Key Phase 3 Trial 6/3/2014
Incyte Corporation (INCY) Release: Pivotal Phase 3 Data In Polycythemia Vera Show That Jakafi® (Ruxolitinib) Achieved Superior Disease Control Compared To Best Available Therapies 6/3/2014
CEL-SCI (CVM) Reports Continued Increase In Sequential Quarterly Patient Enrollment In Its Phase 3 Head And Neck Cancer Trial 6/3/2014
Pivotal Data For Novartis AG (NVS)'s LDE225 Promising In Phase 2 Basal Cell Carcinoma Trial 6/2/2014
Eisai Inc. (ESALF.PK)'s New Thyroid Cancer Drug Lenvatinib Shows Promise In Phase 3 Study 6/2/2014
New Detailed Phase 3 Data Show Amgen (AMGN)'s Novel Cholesterol Drug Evolocumab Significantly Reduced LDL Cholesterol 6/2/2014
Merck & Co., Inc. (MRK) Immune System-Booster MK3475 Effective In Skin, Lung Cancer 6/2/2014
Janssen Pharmaceutical Inc. Release: Ibrutinib (IMBRUVICA®) Three Year Follow-Up Of Single-Agent And Combination Study Results In Chronic Lymphocytic Leukemia 6/2/2014
Oxygen Biotherapeutics, Inc. (OXBT) Announces Formation Of Steering Committee For Phase 3 LEVO-CTS Trial Of Levosimendan 6/2/2014
Medivation, Inc. (MDVN) Release: The New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial Of Enzalutamide In Men With Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy 6/2/2014
CEL-SCI (CVM) Receives Approval To Expand Its Immunotherapy Phase 3 Head And Neck Cancer Trial Into The United Kingdom 6/2/2014
Astellas Pharma Inc. (ALPMY) Release: The New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial Of Enzalutamide In Men With Chemotherapy-Naïve Metastatic Prostate Cancer 6/2/2014
Forest Laboratories, Inc. (FRX) Announces Publication In Lancet Of Pivotal Phase III Hypertension Trial Of The Fixed-Dose Combination Of Nebivolol/Valsartan 6/2/2014
Tesaro, Inc. (TSRO) Summarizes Phase 3 Rolapitant Data Presented At The 2014 American Society of Clinical Oncology Annual Meeting And Provides An Update On Niraparib Development Strategy 6/2/2014
Ariad Pharmaceuticals, Inc. (ARIA) Announces Preliminary Safety And Efficacy Data Of Ponatinib In Patients With Newly Diagnosed CML From Discontinued Phase 3 EPIC Trial 6/2/2014
Janssen-Cilag International NV Release: Phase 3 Data Highlight Benefits Of Using VELCADE® Within Frontline Treatment Of Mantle Cell Lymphoma, With Results Showing Significantly Longer Progression-Free Survival Compared To Standard Of Care 6/2/2014
Celgene (CELG) Release: Post-Hoc Analysis Of Overall Survival In Phase III MPACT Study Of Patients With Advanced Pancreatic Cancer Presented At American Society of Clinical Oncology 2014 6/2/2014
Millennium Release: VELCADE®: (Bortezomib)-Based Therapy Significantly Improved Progression-Free Survival Compared To Standard Therapy As Frontline Treatment Of Patients With Mantle Cell Lymphoma In Phase 3 Study 6/2/2014
The New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial Of Enzalutamide In Men With Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy 6/2/2014
First Presentation Of Data For Pembrolizumab, Merck & Co., Inc. (MRK)’s Investigational Anti-PD-1 Antibody, In Patients With Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) At American Society of Clinical Oncology 2014 6/2/2014



//-->